10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

FORM 10-Q

(Mark One)

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2010

or

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from              to             

Commission File Number: 0-24260

AMEDISYS, INC.

(Exact Name of Registrant as Specified in its Charter)

Delaware	11-3131700
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

5959 S. Sherwood Forest Blvd., Baton Rouge, LA 70816

(Address of principal executive offices, including zip code)

(225) 292-2031 or (800) 467-2662

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  x    No  ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes  x    No  ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer	x	Accelerated filer	¨
Non-accelerated filer	¨  (Do not check if a smaller reporting company)	Smaller reporting company	¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ¨    No  x

The number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date, is as follows: Common stock, $0.001 par value, 28,820,619 shares outstanding as of August 4, 2010.

TABLE OF CONTENTS

SPECIAL CAUTION CONCERNING FORWARD-LOOKING STATEMENTS AND AVAILABLE INFORMATION		1
PART I. FINANCIAL INFORMATION
ITEM 1.	FINANCIAL STATEMENTS (UNAUDITED):
	CONDENSED CONSOLIDATED BALANCE SHEETS AS OF JUNE 30, 2010 AND DECEMBER 31, 2009	2
	CONDENSED CONSOLIDATED INCOME STATEMENTS FOR THE THREE AND SIX-MONTH PERIODS ENDED JUNE 30, 2010 AND 2009	3
	CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE SIX-MONTH PERIODS ENDED JUNE 30, 2010 AND 2009	4
	NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS	5
ITEM 2.	MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS	13
ITEM 3.	QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK	24
ITEM 4.	CONTROLS AND PROCEDURES	24
PART II. OTHER INFORMATION
ITEM 1.	LEGAL PROCEEDINGS	25
ITEM 1A.	RISK FACTORS	25
ITEM 2.	UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS	26
ITEM 3.	DEFAULTS UPON SENIOR SECURITIES	26
ITEM 4.	RESERVED	26
ITEM 5.	OTHER INFORMATION	26
ITEM 6.	EXHIBITS	27
SIGNATURES		29
INDEX TO EXHIBITS		30

SPECIAL CAUTION CONCERNING FORWARD-LOOKING STATEMENTS AND AVAILABLE INFORMATION

Special Caution Concerning Forward-Looking Statements

When included in this Quarterly Report on Form 10-Q, or in other documents that we file with the Securities and Exchange Commission (“SEC”) or in statements made by or on behalf of our company, words like “believes,” “belief,” “expects,” “plans,” “anticipates,” “intends,” “projects,” “estimates,” “may,” “might,” “would,” “should” and similar expressions are intended to identify forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a variety of risks and uncertainties that could cause actual results to differ materially from those described therein. These risks and uncertainties include, but are not limited to the following: changes in Medicare and other medical payment levels, our ability to open agencies, acquire additional agencies and integrate and operate these agencies effectively, changes in or our failure to comply with existing Federal and State laws or regulations or the inability to comply with new government regulations on a timely basis, competition in the home health industry, changes in the case mix of patients and payment methodologies, changes in estimates and judgments associated with critical accounting policies, our ability to maintain or establish new patient referral sources, our ability to attract and retain qualified personnel, changes in payments and covered services due to the economic downturn and deficit spending by Federal and State governments, future cost containment initiatives undertaken by third-party payors, our access to financing due to the volatility and disruption of the capital and credit markets, our ability to meet debt service requirements and comply with covenants in debt agreements, business disruptions due to natural disasters or acts of terrorism, our ability to integrate and manage our information systems, changes in or developments with respect to any litigation or investigations relating to the Company, including the United States Senate Committee on Finance inquiry and the SEC investigation and various other matters, many of which are beyond our control.

Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on any forward-looking statement as a prediction of future events. We expressly disclaim any obligation or undertaking and we do not intend to release publicly any updates or changes in our expectations concerning the forward-looking statements or any changes in events, conditions or circumstances upon which any forward-looking statement may be based, except as required by law. For a discussion of some of the factors discussed above as well as additional factors, see our Annual Report on Form 10-K for the year ended December 31, 2009, filed with the SEC on February 23, 2010, particularly Part I, Item 1A. – “Risk Factors” therein, which are incorporated herein by reference and Part II, Item 1A. – “Risk Factors” of this Quarterly Report on Form 10-Q. Additional risk factors may also be described in reports that we file from time to time with the SEC.

Available Information

Our company website address is www.amedisys.com. We use our website as a channel of distribution for important company information. Important information, including press releases, analyst presentations and financial information regarding our company, is routinely posted on and accessible on the Investor Relations subpage of our website, which is accessible by clicking on the tab labeled “Investors” on our website home page. We also use our website to expedite public access to time-critical information regarding our company in advance of or in lieu of distributing a press release or a filing with the SEC disclosing the same information. Therefore, investors should look to the Investor Relations subpage of our website for important and time-critical information. Visitors to our website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations subpage of our website. In addition, we make available on the Investor Relations subpage of our website (under the link “SEC filings”) free of charge our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, ownership reports on Forms 3, 4 and 5 and any amendments to those reports as soon as practicable after we electronically file such reports with the SEC. Further, copies of our Certificate of Incorporation and Bylaws, our Code of Ethical Business Conduct, Corporate Governance Guidelines and the charters for the Audit, Compensation and Nominating and Corporate Governance Committees of our Board are also available on the Investor Relations subpage of our website (under the link “Corporate Governance”).

Additionally, our filings can also be obtained at the SEC’s Public Reference Room at 100 F Street, NE, Room 1580, Washington, D.C. 20549. Information on the operation of the Public Reference Room may be obtained by calling the SEC at (800) SEC-0330. Our electronically filed reports can also be obtained on the SEC’s internet site at http://www.sec.gov.

1

PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

AMEDISYS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(Amounts in thousands, except share data)

(Unaudited)

	June 30, 2010			December 31, 2009
ASSETS
Current assets:
Cash and cash equivalents	$	116,027		$	34,485
Patient accounts receivable, net of allowance for doubtful accounts of $24,523 and $26,371		151,855			150,269
Prepaid expenses		11,713			10,279
Other current assets		10,776			23,003
Total current assets		290,371			218,036
Property and equipment, net of accumulated depreciation of $71,790 and $59,780		112,143			91,919
Goodwill		790,210			786,923
Intangible assets, net of accumulated amortization of $14,792 and $11,824		57,732			57,608
Other assets, net		18,764			17,865
Total assets	$	1,269,220		$	1,172,351
LIABILITIES AND EQUITY
Current liabilities:
Accounts payable	$	22,968		$	16,535
Payroll and employee benefits		119,549			119,619
Accrued expenses		36,650			33,035
Obligations due Medicare		4,618			4,618
Current portion of long-term obligations		41,773			44,254
Current portion of deferred income taxes		12,679			11,245
Total current liabilities		238,237			229,306
Long-term obligations, less current portion		162,349			170,899
Deferred income taxes		34,039			29,399
Other long-term obligations		7,074			6,412
Total liabilities		441,699			436,016
Commitments and Contingencies - Note 6
Equity:
Preferred stock, $0.001 par value, 5,000,000 shares authorized; none issued or outstanding		—			—
Common stock, $0.001 par value, 60,000,000 shares authorized; 28,894,366 and 28,303,216 shares issued; and 28,757,389 and 28,191,174 shares outstanding		29			28
Additional paid-in capital		387,377			363,670
Treasury stock at cost, 136,977 and 112,042 shares of common stock		(2,156	)		(735	)
Accumulated other comprehensive income		2			114
Retained earnings		440,937			372,089
Total Amedisys, Inc. stockholders’ equity		826,189			735,166
Noncontrolling interests		1,332			1,169
Total equity		827,521			736,335
Total liabilities and equity	$	1,269,220		$	1,172,351

The accompanying notes are an integral part of these condensed consolidated financial statements.

2

AMEDISYS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED INCOME STATEMENTS

(Amounts in thousands, except per share data)

(Unaudited)

	For the three-month periods ended June 30,						For the six-month periods ended June 30,
	2010			2009			2010			2009
Net service revenue	$	422,349		$	377,892		$	835,316		$	719,731
Cost of service, excluding depreciation and amortization		209,302			178,437			413,364			343,477
General and administrative expenses:
Salaries and benefits		89,210			82,055			176,709			155,080
Non-cash compensation		3,168			2,779			5,681			4,920
Other		51,799			42,425			96,447			84,691
Provision for doubtful accounts		4,463			5,737			8,808			11,903
Depreciation and amortization		8,279			6,919			16,465			13,201
Operating expenses		366,221			318,352			717,474			613,272
Operating income		56,128			59,540			117,842			106,459
Other (expense) income:
Interest income		92			52			177			133
Interest expense		(2,350	)		(2,958	)		(4,761	)		(6,412	)
Equity in earnings from unconsolidated joint ventures		734			642			1,522			1,066
Miscellaneous, net		(1,575	)		301			(1,374	)		655
Total other expense, net		(3,099	)		(1,963	)		(4,436	)		(4,558	)
Income before income taxes		53,029			57,577			113,406			101,901
Income tax expense		(20,663	)		(22,455	)		(44,210	)		(39,741	)
Net income		32,366			35,122			69,196			62,160
Net income attributable to noncontrolling interests		(164	)		(39	)		(348	)		(55	)
Net income attributable to Amedisys, Inc.	$	32,202		$	35,083		$	68,848		$	62,105
Net income per share attributable to Amedisys, Inc. common stockholders:
Basic	$	1.15		$	1.29		$	2.46		$	2.30
Diluted	$	1.13		$	1.27		$	2.42		$	2.26
Weighted average shares outstanding:
Basic		28,106			27,124			27,963			26,989
Diluted		28,597			27,541			28,478			27,427

The accompanying notes are an integral part of these condensed consolidated financial statements.

3

AMEDISYS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Amounts in thousands)

(Unaudited)

	For the six-month periods ended June 30,
	2010			2009
Cash Flows from Operating Activities:
Net income	$	69,196		$	62,160
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization		16,465			13,201
Provision for doubtful accounts		8,808			11,903
Non-cash compensation		5,681			4,920
401(k) employer match		11,467			9,581
Loss on disposal of property and equipment		2,019			535
Deferred income taxes		6,074			5,154
Equity in earnings of unconsolidated joint ventures		(1,522	)		(1,066	)
Amortization of deferred debt issuance costs		788			788
Return on equity investment		840			150
Changes in operating assets and liabilities, net of impact of acquisitions:
Patient accounts receivable		(10,395	)		9,465
Other current assets		11,120			(2,020	)
Other assets		(2,777	)		1,775
Accounts payable		5,436			1,754
Accrued expenses		1,571			9,489
Other long-term obligations		663			2,509
Net cash provided by operating activities		125,434			130,298
Cash Flows from Investing Activities:
Proceeds from sale of deferred compensation plan assets		2,340			956
Proceeds from the sale of property and equipment		—			3
Purchases of deferred compensation plan assets		(1,018	)		(2,969	)
Purchases of property and equipment		(23,910	)		(15,056	)
Acquisitions of businesses, net of cash acquired		(2,721	)		(19,205	)
Acquisitions of reacquired franchise rights		(2,377	)		(5,214	)
Net cash (used in) investing activities		(27,686	)		(41,485	)
Cash Flows from Financing Activities:
Outstanding checks in excess of bank balance		—			(3,379	)
Proceeds from issuance of stock upon exercise of stock options and warrants		1,358			454
Proceeds from issuance of stock to employee stock purchase plan		3,012			2,734
Tax benefit from stock option exercises		2,192			637
Non-controlling interest distribution		(185	)		—
Proceeds from revolving line of credit		—			50,200
Repayments of revolving line of credit		—			(119,700	)
Principal payments of long-term obligations		(22,583	)		(21,708	)
Net cash (used in) financing activities		(16,206	)		(90,762	)
Net increase in cash and cash equivalents		81,542			(1,949	)
Cash and cash equivalents at beginning of period		34,485			2,847
Cash and cash equivalents at end of period	$	116,027		$	898
Supplemental Disclosures of Cash Flow Information:
Cash paid for interest	$	4,266		$	5,920
Cash paid for income taxes, net of refunds received	$	31,870		$	27,915
Supplemental Disclosures of Non-Cash Financing and Investing Activities:
Notes payable issued for acquisitions	$	750		$	3,834
Notes payable issued for software licenses	$	10,801		$	—

The accompanying notes are an integral part of these condensed consolidated financial statements.

4

AMEDISYS, INC. AND SUBSIDIARIES

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

1. NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS

Amedisys, Inc., a Delaware corporation, and its consolidated subsidiaries (“Amedisys,” “we,” “us,” or “our”) are a multi-state provider of home health and hospice services with approximately 86% and 87% of our revenue derived from Medicare for the three-month periods ended June 30, 2010 and 2009, respectively and approximately 87% of our revenue derived from Medicare for the six-month periods ended June 30, 2010 and 2009. As of June 30, 2010, we had 529 Medicare-certified home health and 72 Medicare-certified hospice agencies in 45 states within the United States, the District of Columbia and Puerto Rico.

Basis of Presentation

In our opinion, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting solely of normal recurring adjustments) necessary to present fairly our financial position, our results of operations and our cash flows in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). Our results of operations for the interim periods presented are not necessarily indicative of results of our operations for the entire year and have not been audited by our independent auditors.

Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from the interim financial information presented. This report should be read in conjunction with our consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December 31, 2009 as filed with the Securities and Exchange Commission (“SEC”) on February 23, 2010 (the “Form 10-K”), which includes information and disclosures not included herein.

Use of Estimates

Our accounting and reporting policies conform with U.S. GAAP. In preparing the unaudited condensed consolidated financial statements, we are required to make estimates and assumptions that impact the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates.

Reclassifications and Comparability

Certain reclassifications have been made to prior periods’ financial statements in order to conform them to the current period’s presentation.

As a result of our rapid growth through acquisition and start-up activities, our operating results may not be comparable for the periods that are presented.

Principles of Consolidation

These unaudited condensed consolidated financial statements include the accounts of Amedisys, Inc. and our wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in our accompanying unaudited condensed consolidated financial statements, and business combinations accounted for as purchases have been included in our unaudited condensed consolidated financial statements from their respective dates of acquisition. In addition to our wholly owned subsidiaries, we also have certain equity investments that are accounted for as set forth below.

Equity Investments

We consolidate subsidiaries and/or joint ventures when the entity is a variable interest entity and we are the primary beneficiary or if we have controlling interests in the entity, which is generally ownership in excess of 50%. Third party equity interests in our consolidated joint ventures are reflected as noncontrolling interests in our condensed consolidated financial statements.

For subsidiaries or joint ventures in which we do not have a controlling interest or for which we are not the primary beneficiary, we record such investments under the equity method of accounting.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Revenue Recognition

We earn net service revenue through our home health and hospice agencies by providing a variety of services almost exclusively in the homes of our patients. This net service revenue is earned and billed either on an episode of care basis (on a 60-day episode of care

5

basis for home health services and on a 90-day episode of care basis for the first two hospice episodes of care and on a 60-day episode of care basis for any subsequent hospice episodes), on a per visit basis or on a daily basis depending upon the payment terms and conditions established with each payor for services provided. We refer to home health revenue earned and billed on a 60-day episode of care as episodic-based revenue. For the services we provide, Medicare is our largest payor.

When we record our service revenue, we record it net of estimated revenue adjustments and contractual adjustments to reflect amounts we estimate to be realizable for services provided, as discussed below. We believe, based on information currently available to us and based on our judgment, that changes to one or more factors that impact the accounting estimates (such as our estimates related to revenue adjustments, contractual adjustments and episodes in progress) we make in determining net service revenue, which changes are likely to occur from period to period, will not materially impact our reported consolidated financial condition, results of operations, cash flows or our future financial results.

Home Health Revenue Recognition

Medicare Revenue

Net service revenue is recorded under the Medicare payment program (“PPS”) based on a 60-day episode payment rate that is subject to adjustment based on certain variables including, but not limited to: (a) an outlier payment if our patient’s care was unusually costly (capped at 10% of total reimbursement); (b) a low utilization adjustment (“LUPA”) if the number of visits was fewer than five; (c) a partial payment if our patient transferred to another provider or we received a patient from another provider before completing the episode; (d) a payment adjustment based upon the level of therapy services required (thresholds set at 6, 14 and 20 visits); (e) the number of episodes of care provided to a patient, regardless of whether the same home health provider provided care for the entire series of episodes; (f) changes in the base episode payments established by the Medicare Program; (g) adjustments to the base episode payments for case mix and geographic wages; and (h) recoveries of overpayments.

We make adjustments to Medicare revenue on completed episodes to reflect differences between estimated and actual payment amounts, an inability to obtain appropriate billing documentation or authorizations acceptable to the payor and other reasons unrelated to credit risk. We estimate the impact of such adjustments based on our historical experience, which primarily includes a historical collection rate of over 99% on Medicare claims, and record this estimate during the period in which services are rendered as an estimated revenue adjustment and a corresponding reduction to patient accounts receivable. Therefore, we believe that our reported net service revenue and patient accounts receivable will be the net amounts to be realized from Medicare for services rendered.

In addition to revenue recognized on completed episodes, we also recognize a portion of revenue associated with episodes in progress. Episodes in progress are 60-day episodes of care that begin during the reporting period, but were not completed as of the end of the period. We estimate this revenue on a monthly basis based upon historical trends. The primary factors underlying this estimate are the number of episodes in progress at the end of the reporting period, expected Medicare revenue per episode and our estimate of the average percentage complete based on visits performed. As of June 30, 2010 and 2009, the difference between the cash received from Medicare for a request for anticipated payment (“RAP”) on episodes in progress and the associated estimated revenue was immaterial and included as a reduction to our outstanding patient accounts receivable in our condensed consolidated balance sheets for such periods.

Non-Medicare Revenue

Episodic-based Revenue. We recognize revenue in a similar manner as we recognize Medicare revenue for episodic-based rates that are paid by other insurance carriers, including Medicare Advantage programs; however, these rates can vary based upon the negotiated terms.

Non-episodic Based Revenue. Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to our established or estimated per-visit rates, as applicable. Contractual adjustments are recorded for the difference between our standard rates and the contracted rates to be realized from patients, third parties and others for services provided and are deducted from gross revenue to determine net service revenue and are also recorded as a reduction to our outstanding patient accounts receivable. In addition, we receive a minimal amount of our net service revenue from patients who are either self-insured or are obligated for an insurance co-payment.

Hospice Revenue Recognition

Hospice Medicare Revenue

Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to the estimated payment rates. The estimated payment rates are daily or hourly rates for each of the four levels of care we deliver. The four main levels of care we provide are routine care, general inpatient care, continuous home care and respite care. We make adjustments to Medicare revenue for

6

an inability to obtain appropriate billing documentation or authorizations acceptable to the payor and other reasons unrelated to credit risk. We estimate the impact of these adjustments based on our historical experience, which primarily includes our historical collection rate on Medicare claims, and record it during the period services are rendered as an estimated revenue adjustment and as a reduction to our outstanding patient accounts receivable.

Additionally, as Medicare hospice revenue is subject to an inpatient cap limit and an overall payment cap, we monitor our provider numbers and estimate amounts due back to Medicare if a cap has been exceeded. We record these adjustments as a reduction to revenue and increase other accrued liabilities. As of June 30, 2010 and December 31, 2009, we had $0.6 million and $0.1 million, respectively, recorded for estimated amounts due back to Medicare in other accrued liabilities in our accompanying condensed consolidated balance sheets. As a result of our adjustments, we believe our revenue and patients accounts receivable are recorded at amounts that will be ultimately realized.

Hospice Non-Medicare Revenue

We record gross revenue on an accrual basis based upon the date of service at amounts equal to our established rates or estimated per visit rates, as applicable. Contractual adjustments are recorded for the difference between our established rates and the amounts estimated to be realizable from patients, third parties and others for services provided and are deducted from gross revenue to determine our net service revenue and patient accounts receivable.

Patient Accounts Receivable

Our patient accounts receivable are uncollateralized and consist of amounts due from Medicare, Medicaid, other third-party payors and patients. We believe there is a certain level of credit risk associated with non-Medicare payors. To provide for our non-Medicare patient accounts receivable that could become uncollectible in the future, we establish an allowance for doubtful accounts to reduce the carrying amount to its estimated net realizable value. We believe the credit risk associated with our Medicare accounts, which represent 72% and 77% of our net patient accounts receivable at June 30, 2010 and December 31, 2009, respectively, is limited due to (i) our historical collection rate of over 99% from Medicare and (ii) the fact that Medicare is a U.S. government payor. Accordingly, we do not record an allowance for doubtful accounts for our Medicare patient accounts receivable, which are recorded at their net realizable value after recording estimated revenue adjustments as discussed above. During the three and six-month periods ended June 30, 2010, we recorded $1.5 million and $1.7 million, respectively, in estimated revenue adjustments to Medicare revenue as compared to $1.9 million and $4.0 million during the three and six-month periods ended June 30, 2009, respectively. There is no other single payor, other than Medicare, that accounts for more than 10% of our total outstanding patient receivables, and thus we believe there are no other significant concentrations of receivables that would subject us to any significant credit risk in the collection of our patient accounts receivable.

We fully reserve for accounts which are aged at 360 days or greater. We write off accounts on a monthly basis once we have exhausted our collection efforts and deem an account to be uncollectible.

Medicare Home Health

For our home health patients, our pre-billing process includes verifying that we are eligible for payment from Medicare for the services that we provide to our patients. Our Medicare billing begins with a process to ensure that our billings are accurate through the utilization of an electronic Medicare claim review. We submit a RAP for 60% of our estimated payment for the initial episode at the start of care or 50% of the estimated payment for any subsequent episodes of care contiguous with the first episode for a particular patient. The full amount of the episode is billed after the episode has been completed (“final billed”). The RAP received for that particular episode is then deducted from our final payment. If a final bill is not submitted within the greater of 120 days from the start of the episode, or 60 days from the date the RAP was paid, any RAPs received for that episode will be recouped by Medicare from any other claims in process for that particular provider number. The RAP and final claim must then be re-submitted.

Medicare Hospice

For our hospice patients, our pre-billing process includes verifying that we are eligible for payment from Medicare for the services that we provide to our patients. Once each patient has been confirmed for eligibility, we will bill Medicare on a monthly basis for the services provided to the patient.

Non-Medicare Home Health and Hospice

For our non-Medicare patients, our pre-billing process primarily begins with verifying a patient’s eligibility for services with the applicable payor. Once the patient has been confirmed for eligibility, we will provide services to the patient and bill the applicable payor. We estimate an allowance for doubtful accounts to reduce the carrying amount of the receivables to the amounts we estimate will be ultimately collected. Our review and evaluation of non-Medicare accounts includes a detailed review of outstanding balances

7

and special consideration to concentrations of receivables from particular payors or groups of payors with similar characteristics that would subject us to any significant credit risk. In addition, the amount of the allowance for doubtful accounts is based upon our assessment of historical and expected net collections, business and economic conditions, trends in payment and an evaluation of collectibility based upon the date that the service was provided. Based upon our best judgment, we believe the allowance for doubtful accounts adequately provides for accounts that will not be collected due to credit risk.

Fair Value of Financial Instruments

The following details our financial instruments where the carrying value and fair value differ (amounts in millions):

			Fair Value at Reporting Date Using
Financial Instrument	As of June 30, 2010		Quoted Prices in Active Markets for Identical Items (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Long-term obligations, excluding capital leases	$	204.0	$	—	$	202.5	$	—

The estimates of the fair value of our long-term debt are based upon a discounted present value analysis of future cash flows. Due to the existing uncertainty in the capital and credit markets, the actual rates that would be obtained to borrow under similar conditions could materially differ from the estimates we have used.

The fair value hierarchy is based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value. The three levels of inputs are as follows:

• Level 1 — Quoted prices in active markets for identical assets and liabilities.

• Level 2 — Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

• Level 3 — Unobservable inputs that are supported by little or no market activity and are significant to the fair value of the assets or liabilities.

For our other financial instruments, including our cash and cash equivalents, patient accounts receivable, accounts payable and accrued expenses, we estimate the carrying amounts’ approximate fair value due to their short term maturity. Our deferred compensation plan assets are recorded at fair value.

Weighted-Average Shares Outstanding

Net income per share attributable to Amedisys, Inc. common stockholders, calculated on the treasury stock method, is based on the weighted average number of shares outstanding during the period. The following table sets forth, for the periods indicated, shares used in our computation of the weighted-average shares outstanding, which are used to calculate our basic and diluted net income per share attributable to Amedisys, Inc. common stockholders (amounts in thousands):

	For the three-month periods ended June 30,		For the six-month periods ended June 30,
	2010	2009	2010	2009
Weighted average number of shares outstanding - basic	28,106	27,124	27,963	26,989
Effect of dilutive securities:
Stock options	151	171	163	211
Non-vested stock and stock units	340	246	352	227
Weighted average number of shares outstanding - diluted	28,597	27,541	28,478	27,427

For the three and six-month periods ended June 30, 2010, there were 53,210 and 174 shares, respectively, of additional securities that were anti-dilutive compared to 42,749 and 40,337 shares for the three and six-month periods ended June 30, 2009, respectively.

3. ACQUISITIONS

We complete acquisitions from time to time in order to pursue our strategy of increasing our market presence by expanding our service base and enhancing our position in certain geographic areas as a leading provider of home health and hospice services. The purchase price paid for acquisitions is negotiated through arm’s length transactions, with consideration based on our analysis of, among other things, comparable acquisitions and expected cash flows for each transaction. Acquisitions are accounted for as purchases and are included in our condensed consolidated financial statements from their respective acquisition dates. Goodwill

8

generated from acquisitions is recognized for the excess of the purchase price over tangible and identifiable intangible assets because of the expected contributions of the acquisitions to our overall corporate strategy.

2010 Acquisitions

On February 1, 2010, we acquired certain assets and liabilities of a home health agency in DeQueen, Arkansas for a total purchase price of $2.5 million ($2.0 million in cash and a $0.5 million promissory note). In connection with the acquisition, we recorded substantially the entire purchase price as goodwill ($2.2 million) and other intangibles ($0.3 million).

On April 5, 2010, we acquired certain assets and liabilities of a hospice agency in Killen, Alabama for a total purchase price of $1.0 million ($0.7 million in cash and a $0.3 million promissory note). In connection with the acquisition, we recorded substantially the entire purchase price as goodwill ($1.1 million), other intangibles ($0.1 million) and other liabilities ($0.2 million).

4. GOODWILL AND OTHER INTANGIBLE ASSETS, NET

The following table summarizes the activity related to our goodwill and our other intangible assets, net, as of and for the six-month period ended June 30, 2010 (amounts in millions):

	Goodwill
	Home Health		Hospice		Total
Balances at December 31, 2009	$	719.9	$	67.0	$	786.9
Additions		2.2		1.1		3.3
Balances at June 30, 2010	$	722.1	$	68.1	$	790.2

	Other Intangible Assets, Net
	Certificates of Need and Licenses		Acquired Names of Business (1)			Non-Compete Agreements & Reacquired Franchise Rights (2)			Total
Balances at December 31, 2009		43.4		4.7			9.5			57.6
Additions		0.3		0.1			2.7			3.1
Amortization		—		(0.1	)		(2.9	)		(3.0	)
Balances at June 30, 2010	$	43.7	$	4.7		$	9.3		$	57.7

(1) Acquired Names of Business includes $4.4 million of unamortized acquired names and $0.3 million of amortized acquired names which have a weighted-average amortization period of 2.9 years.

(2) The weighted-average amortization period of our non-compete agreements and reacquired franchise rights is 3.0 and 2.5 years, respectively.

5. LONG-TERM OBLIGATIONS

Long-term debt, including capital lease obligations, consisted of the following for the periods indicated (amounts in millions):

	June 30, 2010			December 31, 2009
Senior Notes:
$35.0 million Series A Notes; semi-annual interest only payments; interest rate at 6.07% per annum; due March 25, 2013	$	35.0		$	35.0
$30.0 million Series B Notes; semi-annual interest only payments; interest rate at 6.28% per annum; due March 25, 2014		30.0			30.0
$35.0 million Series C Notes; semi-annual interest only payments; interest rate at 6.49% per annum; due March 25, 2015		35.0			35.0
$150.0 million Term Loan; $7.5 million principal payments plus accrued interest payable quarterly; interest rate at ABR Rate plus applicable percentage or Eurodollar Rate plus the applicable percentage (1.11% at June 30, 2010); due March 26, 2013		82.5			97.5
Promissory notes		21.5			17.6
Capital leases		0.1			0.1
		204.1			215.2
Current portion of long-term obligations		(41.8	)		(44.3	)
Total	$	162.3		$	170.9

9

Our weighted-average interest rate for our five year Term Loan for the three and six-month periods ended June 30, 2010 was 1.1% as compared to 1.5% and 2.1% for the three and six-month periods ended June 30, 2009, respectively.

As of June 30, 2010, our total leverage ratio (used to compute the margin and commitment fees, described in more detail in Note 6 of the financial statements included in our Form 10-K) was 0.7 and our fixed charge coverage ratio was 2.4.

As of June 30, 2010, our availability under our $250.0 million Revolving Credit Facility was $234.6 million as we had $15.4 million outstanding in letters of credit.

See Note 6 of the financial statements included in our Form 10-K for additional details on our outstanding long-term obligations.

6. COMMITMENTS AND CONTINGENCIES

Legal Proceedings

In addition to the matters referenced in this note, we are involved in legal actions in the normal course of business, some of which seek monetary damages, including claims for punitive damages. We do not believe that these normal course actions, when finally concluded and determined, will have a material impact on our consolidated financial condition, results of operations or cash flows. We are also involved in the legal actions set forth below.

United States Senate Committee on Finance Inquiry

On May 12, 2010, we received a letter of inquiry from the United States Senate Committee on Finance requesting documents and information relating to our policies and practices regarding home therapy visits and therapy utilization trends. A similar letter was sent to the other major publicly traded home healthcare companies. We intend to cooperate with the Committee with respect to its inquiry. No assurances can be given as to the timing of this inquiry or as to the outcome of this inquiry.

Securities Class Action Lawsuits

On June 7, 2010, a putative securities class action complaint was filed in the United States District Court for the Middle District of Louisiana on behalf of all persons who purchased Amedisys securities between February 23, 2010 and May 13, 2010 against the Company and certain of our senior executives alleging violations of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 thereunder. The complaint alleges that we and certain of our senior executives made false and/or misleading statements, as well as failed to disclose material facts, about our business, financial condition, operations and prospects, particularly relating to our policies and practices regarding home therapy visits under the Medicare home health prospective payment system and the related alleged impact on our business, financial condition, operations and prospects. The complaint seeks a determination that the action may be maintained as a class action, an award of unspecified monetary damages and other unspecified relief. No assurances can be given as to the timing or outcome of this complaint.

Additional putative securities class actions were filed in the United States District Court for the Middle District of Louisiana on July 14, July 16, and July 28, 2010. Those actions make allegations similar those included in the June 7, 2010 complaint described above, except that each purports to assert claims on behalf of a different putative class of purchasers of Amedisys securities.

Derivative Actions

On July 2, 2010, an alleged shareholder of the Company filed a derivative lawsuit in the United States District Court for the Middle District of Louisiana, purporting to assert claims on behalf of the Company against certain of our officers and directors. We are named as a nominal defendant in the action. The complaint alleges that our officers and directors breached their fiduciary duties to Amedisys by making allegedly false statements, and by allegedly failing to establish sufficient internal controls over certain of our home health and Medicare billing practices. The complaint seeks an unspecified amount of damages and an order directing Amedisys to adopt certain measures purportedly designed to improve its corporate governance and internal procedures. Three similar derivative suits were filed in the United States District Court for the Middle District of Louisiana on July 15, July 21 and August 2, 2010.

On July 23, 2010, a derivative suit was filed in the Nineteenth Judicial District Court, Parish of East Baton Rouge, State of Louisiana. That action also purports to assert claims on behalf of the Company against certain of our officers and directors, and seeks an unspecified amount of damages and an order directing Amedisys to adopt unspecified measures to improve its corporate governance and internal procedures.

10

SEC Investigation

On June 30, 2010, we received notice of a formal investigation from the SEC and received a subpoena for documents relating to the matters under review by the United States Senate Committee on Finance and other matters involving our operations. We intend to cooperate with the SEC with respect to this investigation. No assurances can be given as to the timing or outcome of this investigation.

We are unable to assess the probable outcome or potential liability, if any, arising from the United States Senate Committee on Finance inquiry, the SEC investigation or the related litigation given the preliminary stage of these matters.

We recognize that additional putative securities class action complaints and other litigation could be filed, and that other investigations and actions could be commenced, relating to matters involving our home therapy visits and therapy utilization trends or other matters.

Insurance

We are obligated for certain costs associated with our insurance programs, including employee health, workers’ compensation and professional liability. While we maintain various insurance programs to cover these risks, we are self-insured for a substantial portion of our potential claims. We recognize our obligations associated with these costs in the period in which a claim is incurred, including with respect to both reported claims and claims incurred but not reported, up to specified deductible limits. These costs have generally been estimated based on historical data of our claims experience. Such estimates, and the resulting reserves, are reviewed and updated by us on a quarterly basis.

Our health insurance has a retention limit of $0.5 million, our workers’ compensation insurance has a retention limit of $0.4 million and our professional liability insurance has a retention limit of $0.3 million.

7. SEGMENT INFORMATION

Our operations involve servicing patients through our two reportable business segments: home health and hospice. Our home health segment delivers a wide range of services in the home of individuals who may be recovering from surgery, have a chronic disability or terminal illness or need assistance with the essential activities of daily living. Our hospice segment provides palliative care and comfort to terminally ill patients and their families. The “other” column in the following tables consists of costs relating to corporate support functions that are not directly attributable to a specific segment.

Management evaluates performance and allocates resources based on the operating income of the reportable segments, which exclude corporate expenses, but includes revenues and all other costs directly attributable to the specific segment. Segment assets are not reviewed by the company’s chief operating decision maker and therefore are not disclosed below. The following table summarizes our segment information for the periods indicated (amounts in millions):

	For the three-month period ended June 30, 2010
	Home Health		Hospice		Other			Total
Net service revenue	$	388.0	$	34.3	$	—		$	422.3
Cost of service, excluding depreciation and amortization		190.7		18.6		—			209.3
General and administrative expenses		91.1		7.9		45.1			144.1
Provision for doubtful accounts		4.0		0.5		—			4.5
Depreciation and amortization		3.9		0.2		4.2			8.3
Operating expenses		289.7		27.2		49.3			366.2
Operating income	$	98.3	$	7.1	$	(49.3	)	$	56.1
	For the three-month period ended June 30, 2009
	Home Health		Hospice		Other			Total
Net service revenue	$	354.7	$	23.2	$	—		$	377.9
Cost of service, excluding depreciation and amortization		166.3		12.1		—			178.4
General and administrative expenses		78.4		5.5		43.5			127.4
Provision for doubtful accounts		5.4		0.3		—			5.7
Depreciation and amortization		3.3		0.2		3.4			6.9
Operating expenses		253.4		18.1		46.9			318.4
Operating income	$	101.3	$	5.1	$	(46.9	)	$	59.5

11

	For the six-month period ended June 30, 2010
	Home Health		Hospice		Other			Total
Net service revenue	$	768.5	$	66.8	$	—		$	835.3
Cost of service, excluding depreciation and amortization		377.7		35.7		—			413.4
General and administrative expenses		177.4		15.7		85.7			278.8
Provision for doubtful accounts		7.8		1.0		—			8.8
Depreciation and amortization		7.5		0.3		8.7			16.5
Operating expenses		570.4		52.7		94.4			717.5
Operating income	$	198.1	$	14.1	$	(94.4	)	$	117.8
	For the six-month period ended June 30, 2009
	Home Health		Hospice		Other			Total
Net service revenue	$	676.2	$	43.5	$	—		$	719.7
Cost of service, excluding depreciation and amortization		319.8		23.6		—			343.4
General and administrative expenses		149.9		10.7		84.2			244.8
Provision for doubtful accounts		11.3		0.6		—			11.9
Depreciation and amortization		6.5		0.4		6.3			13.2
Operating expenses		487.5		35.3		90.5			613.3
Operating income	$	188.7	$	8.2	$	(90.5	)	$	106.4

8. SUBSEQUENT EVENT

On August 6, 2010, our Board of Directors authorized a stock repurchase program of up to $60.0 million of our common stock. Purchases may be made through open market and privately negotiated transactions, at times and in such amounts as management deems appropriate, including pursuant to one or more Rule 10b5-1 trading plans. The share repurchase program is scheduled to expire on September 30, 2011.

The timing of any repurchases and the actual number of shares repurchased will depend on a variety of factors, including the price of our common stock, corporate and regulatory requirements, restrictions under our debt obligations and other market and economic conditions. The stock repurchase program does not obligate Amedisys to acquire any particular amount of stock and may be modified, suspended or discontinued at any time.

12

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion and analysis provides information we believe is relevant to an assessment and understanding of our results of operations and financial condition for the three and six-month periods ended June 30, 2010. This discussion should be read in conjunction with the condensed consolidated financial statements and notes thereto included herein, the consolidated financial statements and notes and the related Management’s Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form 10-K for the year ended December 31, 2009 filed with the Securities and Exchange Commission (“SEC”) on February 23, 2010 (the “Form 10-K”), which are incorporated herein by this reference.

Unless otherwise provided, “Amedisys,” “we,” “us,” “our” and the “Company” refer to Amedisys, Inc. and our consolidated subsidiaries.

Overview

We are a leading provider of high-quality, low-cost home health services to the chronic, co-morbid, aging American population. Our services include home health and hospice services, and approximately 86% and 87% of our revenue was derived from Medicare for the three-month periods ended June 30, 2010 and 2009, respectively and approximately 87% of our revenue was derived from Medicare for the six-month periods ended June 30, 2010 and 2009. During the three-month period ended June 30, 2010, we had $422.3 million in net service revenue, earnings per diluted share of $1.13 and cash flow from operations of $54.4 million. For the six-month period ended June 30, 2010, we had $835.3 million in net service revenue, earnings per diluted share of $2.42 and cash flow from operations of $125.4 million.

During the three-month period ended June 30, 2010, we incurred costs of approximately $7.9 million ($4.8 million net of tax) primarily associated with our realignment of our operations including legal, training, agency closings, severance, as well as the United States Senate Committee on Finance inquiry and SEC investigations discussed in Note 6 to the condensed consolidated financial statements. These costs were offset by $3.1 million ($1.9 million net of tax) for the reversal of accrued bonuses. Additionally, we received a $3.5 million ($2.1 million net of tax) Centers for Medicare and Medicaid Services (“CMS”) bonus payment as the result of the pay for performance demonstration. The net effect of these items on reported net income is a reduction of $0.8 million or approximately 3 cents per share.

During the three-month period ended June 30, 2010, we began an evaluation of the performance of our current portfolio of agencies and our pipeline of start-up agencies. As a result, we merged 10 operating home health agencies with agencies servicing the same markets, closed 2 operating home health agencies and exited 10 unopened home health start-up locations which were incurring expenses. As part of the closing of these locations, we recorded $1.4 million in lease liabilities during the three-month period ended June 30, 2010. We will continue to evaluate our portfolio in future quarters. The following details our owned Medicare-certified agencies, which are located in 45 states within the United States, the District of Columbia and Puerto Rico.

	Owned and Operated Agencies
	Home health		Hospice
At December 31, 2009	521		65
Acquisitions	1		1
Start-ups	23		6
Closed	(16	)	—
At June 30, 2010	529		72

Recent Developments

Health Care Reform

In March 2010, President Obama signed into law the Patient Protection and Affordable Care Act (“PPACA”) and the Health Care and Education Reconciliation Act of 2010 (“HCERA”), which amends the PPACA (collectively, the “Health Care Reform Bills”). The Health Care Reform Bills make a number of changes to Medicare payment rates including the reinstatement of the 3% home health rural add-on which began on April 1, 2010 (expiring January 1, 2016) and CMS has recently proposed several changes to Medicare home health payments for 2011 as discussed below.

The Health Care Reform Bills also include a systemic rebasing phased in over four years, beginning in 2014. We anticipate that many of the provisions of the Health Care Reform Bills may be subject to further clarification and modification through the rule-making process. It is uncertain at this time the effect the rebasing will have on our future results of operations or cash flows.

13

Additionally, the Health Care Reform Bills expand health care coverage to many uninsured individuals and expands coverage to those already insured. We do not expect any short term impact on our financial results as a result of the legislation. One provision that will impact certain companies significantly is the elimination of the tax deductibility of the Medicare Part D subsidy. This provision does not affect us as we do not provide retiree health benefits.

Payment

On July 16, 2010, CMS issued a proposed rule to update and revise Medicare home health rates for calendar year 2011. The proposed rule includes the following changes to the base rate: a 1.4% market basket increase which includes the 1% reduction mandated by the Health Care Reform Bills, a negative 3.79% case-mix adjustment and a negative 2.5% to reflect the elimination of the one-year shift to half the outlier budget to the base rate. The net effect of these changes decreases the base rate for 2011 by 4.9% to $2,199. CMS has not issued a final rule as of the date of this filing. The final rule is expected to be published in October 2010.

On July 16, 2010, CMS issued a final rule to update and revise the Medicare hospice wage index for fiscal year 2011. The final rule includes a 2.6% increase in the base rate offset by a 0.8% decrease for the updated wage index data and the second year of the 7-year phase out of the budget neutrality adjustment factor. The net effect of the changes increases the base rate for 2011 by 1.8%. This rule is effective October 1, 2010. We do not expect this change to have a material impact on our future results of operations or financial condition.

Results of Operations

Our operating results may not be comparable for the periods presented, primarily as a result of our acquisition and start-up agencies.

When we refer to “base business,” we mean home health and hospice agencies that we have operated for at least the last twelve months; when we refer to “acquisitions,” we mean home health and hospice agencies that we acquired within the last twelve months; and when we refer to “start-ups,” we mean any home health or hospice agency opened by us in the last twelve months. Once an agency has been in operation for a twelve month period, the results for that particular agency are included as part of our base business from that date forward. When we refer to episodic-based revenue, admissions, recertifications or completed episodes, we mean home health revenue, admissions, recertifications or completed episodes of care for those payors that pay on an episodic-basis, which includes Medicare and other insurance carriers, including Medicare Advantage programs.

Three-Month Period Ended June 30, 2010 Compared to the Three-Month Period Ended June 30, 2009

Net Service Revenue

The following table summarizes our net service revenue growth (amounts in millions):

	For the three-month periods ended June 30,
	2010							2009
	Base/Start- ups (2)			Acquisitions		Total		Total			Variance
Home health revenue:
Medicare revenue	$	325.7		$	5.7	$	331.4	$	308.6		$	22.8
Non-Medicare, episodic-based revenue		37.9			—		37.9		29.1			8.8
Total episodic-based revenue		363.6			5.7		369.3		337.7			31.6
Non-Medicare revenue		17.8			0.9		18.7		17.0			1.7
		381.4			6.6		388.0		354.7			33.3
Hospice revenue:
Medicare revenue		28.3			4.0		32.3		22.0			10.3
Non-Medicare revenue		1.8			0.2		2.0		1.2			0.8
		30.1			4.2		34.3		23.2			11.1
Total revenue:
Medicare revenue		354.0			9.7		363.7		330.6			33.1
Non-Medicare revenue		57.5			1.1		58.6		47.3			11.3
	$	411.5		$	10.8	$	422.3	$	377.9		$	44.4
Internal episodic-based revenue growth (1)		8	%						19	%

(1) Internal episodic-based revenue growth is the percent increase in our base/start-up episodic-based revenue for the period as a percent of the total episodic-based revenue of the prior period.

14

(2) Our net service revenue for our base/start-up agencies of $411.5 million included $8.9 million from our start-up agencies.

Our net service revenue increased $44.4 million from 2009 to 2010 and consisted of an increase of $33.3 million in home health revenue and $11.1 million in hospice revenue.

Our home health revenue growth consisted of $19.3 million from our base agencies, $7.4 million from our start-up agencies and $6.6 million from our acquisitions. Included in our home health Medicare revenue is $3.5 million received from CMS for our participation in the pay for performance demonstration. Excluding the CMS bonus payment, our total episodic-based revenue increased $28.1 million or 8%. The increase is primarily related to a 7% increase in our revenue per episode and a 1% growth in volume. The volume growth consisted of a 9% increase in admissions offset by an 8% decrease in recertifications.

Our average episodic-based revenue per completed episode increased from $3,166 to $3,372 as a result of a 1.8% increase in our base rate effective January 1, 2010, a 3% increase in the base rate on rural episodes (approximately 25% of our episodes) completed subsequent to March 31, 2010, and continued deployment and growth in our therapy intensive specialty programs since June 30, 2009.

Our hospice revenue growth consisted of $5.4 million from our base agencies, $1.5 million from our start-up agencies and $4.2 million from our acquisitions. Hospice revenue is primarily impacted by average daily census, levels of care and payment rates. Overall, our average daily census increased from 1,948 in 2009 to 2,837 in 2010 with 2,490 of our census attributable to our base/start-up agencies during the second quarter of 2010. Our patients’ average length of stay was 77 days for 2009 and 87 days for 2010. Our 2010 revenue was impacted by approximately 1.4% due to the annual hospice rate increase effective October 1, 2009.

Home Health Statistics

The following table summarizes our total home health patient admissions, recertifications and completed episodes:

	For the three-month periods ended June 30,
	2010				2009
	Base/Start- ups		Acquisitions	Total	Total		Variance
Admissions:
Medicare	54,082		1,296	55,378	52,541		2,837
Non-Medicare, episodic-based	7,692		6	7,698	5,668		2,030
Total episodic-based	61,774		1,302	63,076	58,209		4,867
Non-Medicare	9,517		571	10,088	8,943		1,145
	71,291		1,873	73,164	67,152		6,012
Internal episodic-based admission growth (1)	6	%			4	%
Recertifications:
Medicare	42,214		477	42,691	47,390		(4,699	)
Non-Medicare, episodic-based	4,868		11	4,879	4,117		762
Total episodic-based	47,082		488	47,570	51,507		(3,937	)
Non-Medicare	4,642		94	4,736	5,526		(790	)
	51,724		582	52,306	57,033		(4,727	)
Internal episodic-based recertification growth (2)	(9	%)			10	%
Completed Episodes:
Medicare	96,188		1,615	97,803	93,352		4,451
Non-Medicare, episodic-based	11,600		17	11,617	8,857		2,760
	107,788		1,632	109,420	102,209		7,211

(1) Internal episodic-based admission growth is the percent increase in our base/start-up episodic-based admissions for the period as a percent of the total episodic-based admissions of the prior period.

(2) Internal episodic-based recertification growth is the percent increase in our base/start-up episodic-based recertifications for the period as a percent of the total episodic-based recertifications of the prior period.

Our internal episodic-based recertification growth has decreased from 10% in the second quarter of 2009 to a negative 9% for the second quarter of 2010. The decline in our rate of recertifications has been the result of changes in our mix of patient diagnosis, an increase in the utilization of Balanced for Life and other multidisciplinary specialty programs that have fewer episodes and external factors that have impacted us and the home health care industry as a whole.

15

Cost of Service, Excluding Depreciation and Amortization

Our cost of service consists of the following expenses incurred by our clinical and clerical personnel in our agencies:

• salaries and related benefits (including health care insurance and workers’ compensation insurance);

• transportation expenses (primarily reimbursed mileage at a standard rate); and

• supplies and services expenses (including payments to contract therapists).

The following summarizes our cost of service, visit and cost per visit information:

	For the three-month periods ended June 30,
	2010						2009
	Base/Start-ups		Acquisitions		Total		Total		Variance
Cost of service (amounts in millions):
Home health	$	187.2	$	3.5	$	190.7	$	166.3	$	24.4
Hospice		16.2		2.4		18.6		12.1		6.5
	$	203.4	$	5.9	$	209.3	$	178.4	$	30.9
Home health:
Visits during the period:
Medicare		1,850,050		27,373		1,877,423		1,802,495		74,928
Non-Medicare, episodic-based		229,785		245		230,030		165,306		64,724
Total episodic-based		2,079,835		27,618		2,107,453		1,967,801		139,652
Non-Medicare		205,832		7,451		213,283		217,714		(4,431	)
		2,285,667		35,069		2,320,736		2,185,515		135,221
Home health cost per visit (1)	$	81.89	$	100.49	$	82.18	$	76.10	$	6.08
Episodic-based visits per completed episode (2)		19.4		16.0		19.4		18.6		0.8

(1) We calculate home health cost per visit as home health cost of service divided by total home health visits during the period.

(2) We calculate episodic-based visits per completed episode as the home health episodic-based visits on completed episodes divided by the home health episodic-based episodes completed during the period.

Our home health cost of service increased $24.4 million on a 135,221 increase in visits. The increase consists of $10.3 million related to the increase in visits with the remainder related to the $6.08 increase in cost per visit. The increase in visits is due to the increase in volume as well as an increase in the number of visits per episode. We carefully monitor our cost per visit in order to deliver high-quality low cost care to our patients. The primary factors contributing to the increase in cost per visit is an increase in the number of therapists employed as well as an increase in the number of clinicians that are being paid on a salary basis. Our intent is to convert salaried clinicians to the per visit model, however, the time to convert may vary due to labor market conditions.

General and Administrative Expenses, Provision for Doubtful Accounts, Depreciation and Amortization and Other Expense, net

The following table summarizes our general and administrative expenses, provision for doubtful accounts, depreciation and amortization expense and other expense, net (amounts in millions):

	For the three-month periods ended June 30,
	2010			2009			Variance
General and administrative expenses:
Salaries and benefits	$	89.2		$	82.1		$	7.1
Non-cash compensation		3.2			2.8			0.4
Rent and utilities		17.3			13.4			3.9
Other		34.5			29.0			5.5
Provision for doubtful accounts		4.5			5.7			(1.2	)
Depreciation and amortization		8.3			6.9			1.4
Other expense, net		(3.1	)		(2.0	)		(1.1	)

The increase in salaries and benefits consists of $5.2 million from base/start-up agencies and corporate office and $1.9 million from newly acquired agencies. The increase in base/start-up agencies is due to the addition of 58 start-ups since June 30, 2009. Salaries

16

and benefits for the three months ended June 30, 2010 benefitted by $3.1 million from the reversal of accrued bonuses and includes additional severance costs of approximately $1.0 million.

Rent and utilities increased $3.9 million, which consisted of an increase of $3.6 million in base/start-up agency and corporate office expenses and the inclusion of $0.3 million in acquisition agency expenses. The $3.6 million increase included $1.4 million in lease liabilities as the result of agency closures during the three-month period ended June 30, 2010.

Other general and administrative expenses increased $5.5 million, which included $1.8 million in legal fees incurred as a result of the Senate Finance Committee inquiry and the SEC investigation.

Our provision for doubtful accounts decreased $1.2 million due to improved cash collections and billing processes resulting in an increase of $44.5 million in cash collections compared to the second quarter of 2009. For additional information on our provision for doubtful accounts see “Liquidity and Capital Resources – Outstanding Patient Accounts Receivable.”

Depreciation and amortization expense increased $1.4 million primarily due to the purchase of equipment and furniture and the development of computer software, which are depreciated over three to seven years.

Other expense, net increased $1.1 million primarily due to $1.8 million loss on disposals of property and equipment which was offset by a $0.6 million decrease in interest expense.

Income Tax Expense

The following table summarizes our income tax expense and estimated income tax rate (amounts in millions, except for estimated income tax rate):

	For the three-month periods ended June 30,
	2010			2009			Variance
Income before income taxes	$	53.0		$	57.6		$	(4.6	)
Income tax (expense)		(20.7	)		(22.5	)		1.8
Estimated income tax rate		39.0	%		39.0	%		—

The decrease in income tax expense of $1.8 million is attributable to a decrease in income before income taxes as our estimated income tax rate remained unchanged from 2009 to 2010.

17

Six-Month Period Ended June 30, 2010 Compared to the Six-Month Period Ended June 30, 2009

Net Service Revenue

The following table summarizes our net service revenue growth (amounts in millions):

	For the six-month period ended June 30,
	2010							2009
	Base/Start-ups (2)			Acquisitions		Total		Total			Variance
Home health revenue:
Medicare revenue	$	647.8		$	12.3	$	660.1	$	588.4		$	71.7
Non-Medicare, episodic-based revenue		70.8			0.1		70.9		53.9			17.0
Total episodic-based revenue		718.6			12.4		731.0		642.3			88.7
Non-Medicare revenue		35.5			2.0		37.5		33.9			3.6
		754.1			14.4		768.5		676.2			92.3
Hospice revenue:
Medicare revenue		54.7			8.4		63.1		41.1			22.0
Non-Medicare revenue		3.2			0.5		3.7		2.4			1.3
		57.9			8.9		66.8		43.5			23.3
Total revenue:
Medicare revenue		702.5			20.7		723.2		629.5			93.7
Non-Medicare revenue		109.5			2.6		112.1		90.2			21.9
	$	812.0		$	23.3	$	835.3	$	719.7		$	115.6
Internal episodic-based revenue growth (1)		12	%						21	%

(1) Internal episodic-based revenue growth is the percent increase in our base/start-up episodic-based revenue for the period as a percent of the total episodic-based revenue of the prior period.

(2) Our net service revenue for our base/start-up agencies of $812.0 million included $20.2 million from our start-up agencies.

Our net service revenue increased $115.6 million from 2009 to 2010 and consisted of an increase of $92.3 million in home health revenue and $23.3 million in hospice revenue.

Our home health revenue growth consisted of $60.2 million from our base agencies, $17.7 million from our start-up agencies and $14.4 million from our acquisitions. Included in our home health Medicare revenue is $3.5 million received from CMS for our participation in the pay for performance demonstration. Excluding the CMS bonus payment, our total episodic-based revenue increased $85.2 million or 13%. The increase is related to a 7% increase in our revenue per episode and a 5% increase in our volume. The volume growth consisted of a 12% increase in admissions offset by a 4% decrease in recertifications.

Our average episodic-based revenue per completed episode increased from $3,102 to $3,328 as a result of a 1.8% increase in our base rate effective January 1, 2010, a 3% increase in the base rate on rural episodes (approximately 25% of our episodes) completed subsequent to March 31, 2010, and continued deployment and growth in our therapy intensive specialty programs.

Our hospice revenue growth consisted of $11.9 million from our base agencies, $2.5 million from our start-up agencies and $8.9 million from our acquisitions. Hospice revenue is primarily impacted by average daily census, levels of care and payment rates. Overall, our average daily census increased from 1,830 in 2009 to 2,733 in 2010 with 2,376 of our census attributable to our base/start-up agencies during 2010. Our patients’ average length of stay was 76 days for 2009 and 87 days for 2010. Our 2010 revenue was impacted by approximately 1.4% due to the annual hospice rate increase effective October 1, 2009.

18

Home Health Statistics

The following table summarizes our total home health patient admissions, recertifications and completed episodes:

	For the six-month period ended June 30,
	2010				2009
	Base/Start-ups		Acquisitions	Total	Total		Variance
Admissions:
Medicare	108,984		3,141	112,125	102,984		9,141
Non-Medicare, episodic-based	16,195		34	16,229	11,337		4,892
Total episodic-based	125,179		3,175	128,354	114,321		14,033
Non-Medicare	18,742		1,338	20,080	18,434		1,646
	143,921		4,513	148,434	132,755		15,679
Internal episodic-based admission growth (1)	10	%			6	%
Recertifications:
Medicare	87,057		1,089	88,146	92,415		(4,269	)
Non-Medicare, episodic-based	9,114		25	9,139	7,856		1,283
Total episodic-based	96,171		1,114	97,285	100,271		(2,986	)
Non-Medicare	9,411		221	9,632	11,295		(1,663	)
	105,582		1,335	106,917	111,566		(4,649	)
Internal episodic-based recertification growth (2)	(4	%)			12	%
Completed Episodes:
Medicare	189,610		3,774	193,384	181,442		11,942
Non-Medicare, episodic-based	21,078		54	21,132	17,066		4,066
Total episodic-based	210,688		3,828	214,516	198,508		16,008

(1) Internal episodic-based admission growth is the percent increase in our base/start-up episodic-based admissions for the period as a percent of the total episodic-based admissions of the prior period.

(2) Internal episodic-based recertification growth is the percent increase in our base/start-up episodic-based recertifications for the period as a percent of the total episodic-based recertifications of the prior period.

Our internal episodic-based recertification growth has decreased from 12% in 2009 to a negative 4% for 2010. The decline in our rate of recertifications has been the result of changes in our mix of patient diagnosis, an increase in the utilization of Balanced for Life and other multidisciplinary specialty programs that have fewer episodes and external factors that have impacted us and the home health care industry as a whole.

19

Cost of Service, Excluding Depreciation and Amortization

The following summarizes our cost of service, visit and cost per visit information:

	For the six-month period ended June 30,
	2010						2009
	Base/Start-ups		Acquisitions		Total		Total		Variance
Cost of service (amounts in millions):
Home health	$	369.2	$	8.5	$	377.7	$	319.9	$	57.8
Hospice		30.5		5.2		35.7		23.6		12.1
	$	399.7	$	13.7	$	413.4	$	343.5	$	69.9
Home health:
Visits during the period:
Medicare		3,699,377		62,554		3,761,931		3,475,172		286,759
Non-Medicare, episodic-based		435,838		937		436,775		315,194		121,581
Total episodic-based		4,135,215		63,491		4,198,706		3,790,366		408,340
Non-Medicare		404,561		16,794		421,355		414,069		7,286
		4,539,776		80,285		4,620,061		4,204,435		415,626
Home health cost per visit (1)	$	81.31	$	106.10	$	81.75	$	76.08	$	5.67
Episodic-based visits per completed episode (2)		19.1		15.1		19.0		18.1		0.9

(1) We calculate home health cost per visit as home health cost of service divided by total home health visits during the period.

(2) We calculate episodic-based visits per completed episode as the home health episodic-based visits on completed episodes divided by the home health episodic-based episodes completed during the period.

Our home health cost of service increased $57.8 million on a 415,626 increase in visits. The increase in visits accounted for $31.6 million of the increase with the remainder from the $5.67 increase in cost per visit. The increase in visits is due to the increase in volume as well as an increase in the number of visits per episode. We carefully monitor our cost per visit in order to deliver high-quality low cost care to our patients. The primary factors contributing to the increase in cost per visit is an increase in the number of therapists employed as well as an increase in the number of clinicians that are being paid on a salary basis. Our intent is to convert salaried clinicians to the per visit model, however, the time to convert may vary due to labor market conditions.

General and Administrative Expenses, Provision for Doubtful Accounts, Depreciation and Amortization and Other Expense, net

The following table summarizes our general and administrative expenses, provision for doubtful accounts, depreciation and amortization expense and other expense, net (amounts in millions):

	For the six-month periods ended June 30,
	2010			2009			Variance
General and administrative expenses:
Salaries and benefits	$	176.7		$	155.1		$	21.6
Non-cash compensation		5.7			4.9			0.8
Rent and utilities		32.4			26.9			5.5
Other		64.0			57.8			6.2
Provision for doubtful accounts		8.8			11.9			(3.1	)
Depreciation and amortization		16.5			13.2			3.3
Other expense, net		(4.4	)		(4.6	)		0.2

Salaries and benefits increased $21.6 million, which consisted of an increase of $17.3 million in base/start-up agencies and corporate office expenses and $4.3 million from newly acquired agencies. The base/start-up agency and corporate office expenses increased by $17.3 million primarily due to increased personnel costs for our field administrative staff and corporate staff necessitated by our internal growth and acquisitions. Salaries and benefits for the six-month period ended June 30, 2010 benefitted by $3.1 million from the reversal of the accrued bonuses and includes additional severance costs of approximately $1.0 million.

Rent and utilities increased $5.5 million, which consisted of an increase of $4.8 million in base/start-up agency and corporate office expenses and the inclusion of $0.7 million in acquisition agency expenses. The $4.8 million increase included $1.4 million in lease liabilities as the result of agency closures during the three-month period ended June 30, 2010.

20

Other general and administrative expenses increased $6.2 million, which included $1.8 million in legal fees incurred as a result of the Senate Finance Committee inquiry and the SEC investigation.

Our provision for doubtful accounts decreased $3.1 million due to improved cash collections and billing processes resulting in an increase of $99.8 million in cash collections compared to the same period in 2009. For additional information on our provision for doubtful accounts see “Liquidity and Capital Resources – Outstanding Patient Accounts Receivable.”

Depreciation and amortization expense increased $3.3 million primarily due to the purchase of equipment and furniture and the development of computer software, which are depreciated over three to seven years.

Other expense, net decreased $0.2 million due to a decrease in interest expense of $1.6 million as we have reduced our outstanding debt by $37.6 million from June 30, 2009 to June 30, 2010. The $1.6 million decrease in interest expense was offset by $2.0 million loss on disposals of property and equipment.

Income Tax Expense

The following table summarizes our income tax expense and estimated income tax rate (amounts in millions, except for estimated income tax rate):

	For the six-month periods ended June 30,
	2010			2009			Variance
Income before income taxes	$	113.4		$	101.9		$	11.5
Income tax (expense)		(44.2	)		(39.7	)		(4.5	)
Estimated income tax rate		39.0	%		39.0	%		—

The increase in income tax expense of $4.5 million is attributable to an increase in income before income taxes as our estimated income tax rate remained unchanged from 2009 to 2010.

LIQUIDITY AND CAPITAL RESOURCES

Cash Flows for the Six-Month Period Ended June 30, 2010 Compared to the Six-Month Period Ended June 30, 2009

The following table summarizes our cash flows for the periods indicated (amounts in millions):

	For the six-month periods ended June 30,
	2010			2009			Variance
Cash provided by operating activities	$	125.4		$	130.3		$	(4.9	)
Cash (used in) investing activities		(27.7	)		(41.4	)		13.7
Cash (used in) financing activities		(16.2	)		(90.8	)		74.6
Net increase in cash and cash equivalents		81.5			(1.9	)		83.4
Cash and cash equivalents at beginning of period		34.5			2.8			31.7
Cash and cash equivalents at end of period	$	116.0		$	0.9		$	115.1

Cash provided by operating activities decreased $4.9 million during 2010 compared to 2009. This decrease is primarily related to the leveling of our patient accounts receivable during the six-month period ended June 30, 2010 compared to the significant improvement in our outstanding patient accounts receivable associated with our 2008 acquisitions during the six month period ended June 30, 2009. See “Outstanding Patient Accounts Receivable” below for further details on our change in outstanding patient accounts receivable.

Cash used in investing activities decreased $13.7 million during 2010 compared to 2009 primarily due to a decrease in acquisition activity offset by an increase in our capital expenditures.

Cash used in financing activities decreased $74.6 million during 2010 compared to 2009 primarily due to a decrease in draws and/or repayments on our revolving credit facility. We have decreased our outstanding long-term obligations net of borrowings by $37.6 million from June 30, 2009.

Liquidity

Typically, our principal source of liquidity is the collection of our patient accounts receivable, primarily through the Medicare program; however, from time to time, we can and do obtain additional sources of liquidity through sales of our equity or by incurrence of additional indebtedness. As of June 30, 2010, we had $116.0 million in cash and cash equivalents and $234.6 million in availability under our $250.0 million Revolving Credit Facility.

21

During the six-month period ended June 30, 2010, we made $18.1 million in routine capital expenditures, which primarily included equipment and furniture and computer software and $5.8 million in capital expenditures related to the implementation of our enterprise resource planning system, which is expected to be fully implemented for 2011. Based on our operating forecasts and our debt service requirements, we believe we will have sufficient liquidity to fund our operations, capital requirements and debt service requirements over the next twelve months and into the foreseeable future.

As we manage our liquidity needs to meet our operating forecasts, debt service requirements and our acquisition and start-up activities, we are monitoring the creditworthiness and solvency of our syndicate of banks that provide the availability of credit under our Revolving Credit Facility as well as the status of the overall equity and credit markets. As of the date of this filing, we do not believe the availability of funds under our Revolving Credit Facility is at risk. If the availability under our current Revolving Credit Facility decreases, we may need to consider adjusting our strategy to meet our operating forecasts, debt service requirements and acquisition and start-up activity needs.

Outstanding Patient Accounts Receivable

Our patient accounts receivable, net increased $1.6 million from December 31, 2009 to June 30, 2010 primarily due to the decrease in our provision for doubtful accounts due to improvements in cash collections. Our cash collection as a percentage of revenue was 99.2% and 96.0% for the three-months ended June 30, 2010 and for the three-months ended December 31, 2009, respectively.

Our patient accounts receivable includes unbilled receivables, which are aged based upon our initial service date. At June 30, 2010, the unbilled patient accounts receivable, as a percentage of gross patient accounts receivable, was 22.5%, or $41.2 million compared to 19.8% or $36.7 million at December 31, 2009. We monitor unbilled receivables on an agency by agency basis to ensure that all efforts are made to bill claims within timely filing deadlines. The timely filing deadlines vary by state for Medicaid and among insurance companies. As of June 30, 2010, agencies acquired during the past twelve months represented $9.3 million or 22.6% of our unbilled accounts receivable compared to $2.0 million or 5.5% as of December 31, 2009.

Our provision for estimated revenue adjustments (which is deducted from our service revenue to determine net service revenue) and provision for doubtful accounts were as follows for the periods indicated (in millions). We fully reserve for both our Medicare and other patient accounts receivable that are aged over 360 days.

	For the three-month periods ended June 30,						For the six-month periods ended June 30,
	2010			2009			2010			2009
Provision for estimated revenue adjustments	$	1.5		$	1.9		$	1.7		$	4.0
Provision for doubtful accounts		4.5			5.7			8.8			11.9
Total	$	6.0		$	7.6		$	10.5		$	15.9
As a percent of revenue		1.4	%		2.0	%		1.3	%		2.2	%

Our provision for estimated revenue adjustments and doubtful accounts as a percent of revenue decreased for both periods in 2010 as compared to the same periods in 2009 due to significant improvement in cash collections since the second quarter of 2009 as evidenced by our reduction in our days revenue outstanding, net since the second quarter of 2009. Accounts receivable aged greater than 90 days decreased $19.0 million and $6.8 million since the second and fourth quarters of 2009, respectively.

22

The following schedule details our patient accounts receivable, net of estimated revenue adjustments, by payor class, aged based upon initial date of service (amounts in millions, except days revenue outstanding, net):

	0-90		91-180		181-365		Over 365		Total
At June 30, 2010:
Medicare patient accounts receivable, net (1)	$	88.4	$	19.1	$	2.4	$	—	$	109.9
Other patient accounts receivable:
Medicaid		6.4		2.8		3.0		1.2		13.4
Private		28.7		12.8		7.7		3.9		53.1
Total	$	35.1	$	15.6	$	10.7	$	5.1	$	66.5
Allowance for doubtful accounts (2)										(24.5	)
Non-Medicare patient accounts receivable, net									$	42.0
Total patient accounts receivable, net									$	151.9
Days revenue outstanding, net (3)										32.5
At December 31, 2009:
Medicare patient accounts receivable, net (1)	$	90.1	$	20.4	$	4.8	$	0.2	$	115.5
Other patient accounts receivable:
Medicaid		6.3		2.7		3.5		2.8		15.3
Private		20.5		10.6		9.7		5.1		45.9
Total	$	26.8	$	13.3	$	13.2	$	7.9	$	61.2
Allowance for doubtful accounts (2)										(26.4	)
Non-Medicare patient accounts receivable, net									$	34.8
Total patient accounts receivable, net									$	150.3
Days revenue outstanding, net (3)										33.9

(1) The following table summarizes the activity and ending balances in our estimated revenue adjustments (amounts in millions), which is recorded to reduce our Medicare outstanding patient accounts receivable to their estimated net realizable value, as we do not estimate an allowance for doubtful accounts for our Medicare claims.

	For the three-month period ended						For the six-month period ended
	June 30, 2010			December 31, 2009			June 30, 2010			December 31, 2009
Balance at beginning of period	$	6.9		$	7.8		$	8.7		$	7.8
Provision for estimated revenue adjustments		1.5			2.9			1.7			4.8
Write offs		(2.0	)		(2.0	)		(4.0	)		(3.9	)
Balance at end of period	$	6.4		$	8.7		$	6.4		$	8.7

Our estimated revenue adjustments were 5.5% and 7.0% of our outstanding Medicare patient accounts receivable at June 30, 2010 and December 31, 2009, respectively.

(2) The following table summarizes the activity and ending balances in our allowance for doubtful accounts (amounts in millions), which is recorded to reduce only our Medicaid and private outstanding patient accounts receivable to their estimated net realizable value.

	For the three-month period ended						For the six-month period ended
	June 30, 2010			December 31, 2009			June 30, 2010			December 31, 2009
Balance at beginning of period	$	25.8		$	28.3		$	26.4		$	30.8
Provision for doubtful accounts		4.5			3.8			8.8			8.3
Write offs		(5.8	)		(5.7	)		(10.7	)		(12.7	)
Balance at end of period	$	24.5		$	26.4		$	24.5		$	26.4

23

Our allowance for doubtful accounts was 36.9% and 43.1% of our outstanding Medicaid and private patient accounts receivable at June 30, 2010 and December 31, 2009, respectively.

(3) Our calculation of days revenue outstanding, net is derived by dividing our ending net patient accounts receivable (i.e. net of estimated revenue adjustments and allowance for doubtful accounts) at June 30, 2010 and December 31, 2009 by our average daily net patient revenue for the three-month periods ended June 30, 2010 and December 31, 2009, respectively.

Indebtedness

Our weighted-average interest rate for our five year Term Loan for the three and six-month periods ended June 30, 2010 was 1.1% as compared to 1.5% and 2.1% for the three and six-month periods ended June 30, 2009, respectively.

As of June 30, 2010, our total leverage ratio (used to compute the margin and commitment fees, described in more detail in Note 6 of the financial statements included in our Form 10-K) was 0.7 and our fixed charge coverage ratio was 2.4.

As of June 30, 2010, our availability under our $250.0 million Revolving Credit Facility was $234.6 million as we had $15.4 million outstanding in letters of credit.

See Note 6 of the financial statements included in our Form 10-K for additional details on our outstanding long-term obligations.

Inflation

We do not believe that inflation has significantly impacted our results of operations.

Critical Accounting Policies

See Part II, Item 7 — Critical Accounting Policies and our consolidated financial statements and related notes in Part IV, Item 15 of our Form 10-K, for accounting policies and related estimates we believe are the most critical to understanding our condensed consolidated financial statements, financial condition and results of operations and which require complex management judgment and assumptions, or involve uncertainties. These critical accounting policies include revenue recognition; patient accounts receivable; insurance; goodwill and intangible assets; and income taxes. There have not been any changes to our significant accounting policies or their application, since we filed our Form 10-K.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Our Revolving Credit Facility and Term Loan carry a floating interest rate which is tied to the Eurodollar rate (i.e. LIBOR) and the Prime Rate and, therefore, our condensed consolidated statements of operations and our condensed consolidated statements of cash flows will be exposed to changes in interest rates. As of June 30, 2010, the total amount of outstanding debt subject to interest rate fluctuations was $82.5 million. A 1.0% interest rate increase would increase interest expense by approximately $0.8 million annually.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

We have established disclosure controls and procedures designed to ensure that information required to be disclosed in our reports filed under the Securities Exchange Act of 1934 (the “Exchange Act”) is recorded, processed, summarized, disclosed and reported within the time periods specified in the SEC’s rules and forms. This information is also accumulated and communicated to our management and Board of Directors to allow timely decisions regarding required disclosure.

In connection with the preparation of this Quarterly Report on Form 10-Q, as of June 30, 2010, under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of the effectiveness of our disclosure controls and procedures, as such term is defined under Rules 13a-15(e) and 15d-15(e) promulgated under the Exchange Act.

Based on this evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective as of June 30, 2010, the end of the period covered by this Quarterly Report.

Changes in Internal Controls

There have been no changes in our internal control over financial reporting (as defined in Exchange Act Rule 13a-15(f)) that have occurred during the quarter ended June 30, 2010, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

24

Inherent Limitations on Effectiveness of Controls

Our management, including our principal executive officer and principal financial officer, does not expect that our disclosure controls or our internal controls over financial reporting will prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system’s objectives will be met. The design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Projections of any evaluation of controls’ effectiveness to future periods are subject to risks. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies and procedures.

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

See Note 6 to the condensed consolidated financial statements for information concerning our legal proceedings.

ITEM 1A. RISK FACTORS

In addition to the other information set forth in this Quarterly Report on Form 10-Q, you should carefully consider the risk factors included in Part I, “Item 1A. — “Risk Factors” of our Annual Report on Form 10-K. These risk factors could materially impact our business, financial condition and/or operating results. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely impact our business, financial condition and/or operating results. The risk factors listed below supplement the risk factors included in our Annual Report on Form 10-K.

We are the subject of a number of inquiries by the federal government, any of which could result in substantial penalties against us.

We are the subject of a number of inquiries by the federal government. We have received a letter of inquiry from the United States Senate Committee on Finance requesting documents and information relating to our policies and practices regarding home therapy visits and therapy utilization trends. A similar letter was sent to the other major publicly traded home healthcare companies. In addition, we received a notice of formal investigation from the SEC and received a subpoena for documents relating to the matters under review by the United States Senate Committee on Finance and other matters involving our operations. We are cooperating with these investigations and are responding to these requests. However, we cannot predict when these investigations will be resolved, the outcome of these investigations or their impact on our business. An adverse outcome in these investigations could include the commencement of civil and/or criminal proceedings, substantial fines, penalties and/or administrative remedies, including the loss of right to participate in the Medicare program. In addition, resolution of these matters could involve the imposition of additional and costly compliance obligations. Finally, if these investigations continue over a long period of time, they could divert the attention of management from the day-to-day operations of our business and impose significant administrative burdens on us. These potential consequences, as well as any adverse outcome from these investigations or other investigations initiated by the government at any time, could have a material adverse effect on our business and our consolidated financial condition, results of operations and cash flows.

25

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

The following table provides the information with respect to purchases made by us of shares of our common stock during each of the months during the three-month period ended June 30, 2010:

Period	(a) Total Number of Shares (or Units) Purchased		(b) Average Price Paid per Share (or Unit)		(c) Total Number of Share (or Units) Purchased as Part of Publicly Announced Plans or Programs	(d) Maximum Number (or Approximate Dollar Value) of Shares (or Units) that May Yet Be Purchased Under the Plans or Programs
April 1, 2010 to April 30, 2010	23,677		$	57.00	—	—
May 1, 2010 to May 31, 2010	272		$	48.38	—	—
June 1, 2010 to June 30, 2010	55		$	48.42	—	—
Total	24,004	(1)	$	56.88	—	—

(1) Represents shares of common stock surrendered to us by certain employees to satisfy tax withholding obligations in connection with the vesting of non-vested stock previously awarded to such employees under our 2008 Omnibus Incentive Compensation Plan.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. RESERVED

ITEM 5. OTHER INFORMATION

None.

26

ITEM 6. EXHIBITS

The exhibits marked with the cross symbol (†) are filed and the exhibits marked with the double cross symbol (††) are furnished with this Form 10-Q. Any exhibits marked with the asterisk symbol (*) are management contracts or compensatory plans or arrangements filed pursuant to Item 601(b)(10)(iii) of Regulation S-K.

Exhibit Number	Document Description	Report or Registration Statement	SEC File or Registration Number	Exhibit or Other Reference
3.1	Composite of Certificate of Incorporation of the Company inclusive of all amendments through June 14, 2007	The Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2007	0-24260	3.1
3.2	Composite of By-Laws of the Company inclusive of all amendments through October 22, 2009	The Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2009	0-24260	3.2
4.1	Common Stock Specimen	The Company’s Registration Statement on Form S-3 filed August 20, 2007	333-145582	4.8
4.2	Note Purchase Agreement dated March 25, 2008 among Amedisys, Inc., Amedisys Holding, L.L.C. and the Purchasers identified on Schedule A thereto, relating to the issuance and sale of (a) $35,000,000 aggregate principal amount of their 5.07% Series A Senior Notes due March 25, 2013 (b) $30,000,000 aggregate principal amount of their 6.28% Series B Senior Notes due March 25, 2014 and (c) $35,000,000 aggregate principal amount of their 6.49% Series C Senior Notes due March 25, 2015	The Company’s Current Report on Form 8-K filed on April 1, 2008	0-24260	4.1
4.3	Form of Series A Note due March 25, 2013 (attached as Exhibit 1 to the Note Purchase Agreement Incorporated by reference as Exhibit 4.4 hereto)	The Company’s Current Report on Form 8-K filed on April 1, 2008	0-24260	4.2
4.4	Form of Series B Note due March 25, 2014 (attached as Exhibit 2 to the Note Purchase Agreement Incorporated by reference as Exhibit 4.4 hereto)	The Company’s Current Report on Form 8-K filed on April 1, 2008	0-24260	4.3
4.5	Form of Series C Note due March 25, 2015 (attached as Exhibit 3 to the Note Purchase Agreement Incorporated by reference as Exhibit 4.4 hereto)	The Company’s Current Report on Form 8-K filed on April 1, 2008	0-24260	4.4
†31.1	Certification of William F. Borne, Chief Executive Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
†31.2	Certification of Dale E. Redman, Chief Financial Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

27

Exhibit Number	Document Description	Report or Registration Statement	SEC File or Registration Number	Exhibit or Other Reference
††32.1	Certification of William F. Borne, Chief Executive Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
††32.2	Certification of Dale E. Redman, Chief Financial Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
††101.INS	XBRL Instance
††101.SCH	XBRL Taxonomy Extension Schema Document
††101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document
††101.LAB	XBRL Taxonomy Extension Labels Linkbase Document
††101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document

28

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

AMEDISYS, INC.
(Registrant)
By:	/s/ Dale E. Redman
	Dale E. Redman
	Chief Financial Officer and       Duly Authorized Officer

DATE: August 9, 2010

29

EXHIBIT INDEX

The exhibits marked with the cross symbol (†) are filed and the exhibits marked with the double cross symbol (††) are furnished with this Form 10-Q. Any exhibits marked with the asterisk symbol (*) are management contracts or compensatory plans or arrangements filed pursuant to Item 601(b)(10)(iii) of Regulation S-K.

Exhibit Number	Document Description	Report or Registration Statement	SEC File or Registration Number	Exhibit or Other Reference
3.1	Composite of Certificate of Incorporation of the Company inclusive of all amendments through June 14, 2007	The Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2007	0-24260	3.1
3.2	Composite of By-Laws of the Company inclusive of all amendments through October 22, 2009	The Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2009	0-24260	3.2
4.1	Common Stock Specimen	The Company’s Registration Statement on Form S-3 filed August 20, 2007	333-145582	4.8
4.2	Note Purchase Agreement dated March 25, 2008 among Amedisys, Inc., Amedisys Holding, L.L.C. and the Purchasers identified on Schedule A thereto, relating to the issuance and sale of (a) $35,000,000 aggregate principal amount of their 5.07% Series A Senior Notes due March 25, 2013 (b) $30,000,000 aggregate principal amount of their 6.28% Series B Senior Notes due March 25, 2014 and (c) $35,000,000 aggregate principal amount of their 6.49% Series C Senior Notes due March 25, 2015	The Company’s Current Report on Form 8-K filed on April 1, 2008	0-24260	4.1
4.3	Form of Series A Note due March 25, 2013 (attached as Exhibit 1 to the Note Purchase Agreement Incorporated by reference as Exhibit 4.4 hereto)	The Company’s Current Report on Form 8-K filed on April 1, 2008	0-24260	4.2
4.4	Form of Series B Note due March 25, 2014 (attached as Exhibit 2 to the Note Purchase Agreement Incorporated by reference as Exhibit 4.4 hereto)	The Company’s Current Report on Form 8-K filed on April 1, 2008	0-24260	4.3
4.5	Form of Series C Note due March 25, 2015 (attached as Exhibit 3 to the Note Purchase Agreement Incorporated by reference as Exhibit 4.4 hereto)	The Company’s Current Report on Form 8-K filed on April 1, 2008	0-24260	4.4
†31.1	Certification of William F. Borne, Chief Executive Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
†31.2	Certification of Dale E. Redman, Chief Financial Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

30

Exhibit Number	Document Description	Report or Registration Statement	SEC File or Registration Number	Exhibit or Other Reference
††32.1	Certification of William F. Borne, Chief Executive Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
††32.2	Certification of Dale E. Redman, Chief Financial Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
††101.INS	XBRL Instance
††101.SCH	XBRL Taxonomy Extension Schema Document
††101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document
††101.LAB	XBRL Taxonomy Extension Labels Linkbase Document
††101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document

31

EX-31.1

Exhibit 31.1

CERTIFICATION

I, William F. Borne, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q for the quarter ended June 30, 2010, of Amedisys, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 9, 2010

/s/ William F. Borne

William F. Borne

Chairman and Chief Executive Officer

32

EX-31.2

Exhibit 31.2

CERTIFICATION

I, Dale E. Redman, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q for the quarter ended June 30, 2010, of Amedisys, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 9, 2010

/s/ Dale E. Redman

Dale E. Redman

Chief Financial Officer

33

EX-32.1

Exhibit 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Amedisys, Inc. (the “Company”) on Form 10-Q for the quarter ended June 30, 2010 (the “Report”), I, William F. Borne, Chairman and Chief Executive Officer of the Company, hereby certify to my knowledge, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 9, 2010

/s/ William F. Borne

William F. Borne

Chairman and Chief Executive Officer

34

EX-32.2

Exhibit 32.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Amedisys, Inc. (the “Company”) on Form 10-Q for the quarter ended June 30, 2010 (the “Report”), I, Dale E. Redman, Chief Financial Officer of the Company, hereby certify to my knowledge, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 9, 2010

/s/ Dale E. Redman

Dale E. Redman

Chief Financial Officer

35